SCHEMBL3028108

SCHEMBL3028108

CC(=O)c1ccc(N2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.69
ALDH1A1 P00352 6/20 0.69
KMT2A Q03164 5/20 0.69
MEN1 O00255 2/20 0.63
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.57
POLB P06746 1/20 0.57
KDM4E B2RXH2 1/20 0.57
LMNA P02545 1/20 0.57
CRHBP P24387 1/20 0.56
HTT P42858 1/20 0.56
CRHR2 Q13324 1/20 0.56
MAPK1 P28482 2/20 0.55
TP53 P04637 1/20 0.55
THRB P10828 1/20 0.55
PANK3 Q9H999 1/20 0.55
CASP6 P55212 1/20 0.53
GFER P55789 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylformamide SCHEMBL27741256 0.89 MAPT (0.57) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL17669252 0.89 MAPT (0.71) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL15801114 0.89 MAPT (0.71) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL1483566 0.87 MAPT (0.71) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL9531913 0.85 NPC1 (0.68) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL335061 0.85 KDM4E (0.61) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL4976412 0.84 LMNA (0.52) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL1484133 0.84 MAPT (0.67) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL1372140 0.84 MAPT (0.66) MAPTALDH1A1KMT2AMEN1NPC1
SCHEMBL1481892 0.83 POLB (0.72) MAPTALDH1A1KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN claimed
US-9688696-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2017-06-27 US disclosed
US-20170029440-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-02-02 US disclosed
US-9499567-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2016-11-22 US disclosed
US-20150322088-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-11-12 US disclosed
EP-2152271-B1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-21 EP disclosed
US-9120821-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2015-09-01 US disclosed
US-20140350012-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-11-27 US disclosed
US-8835437-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2014-09-16 US disclosed
CN-101448802-B Acrylamide derivative as histone deacetylase inhibitors for cancer treatment DAC SRL 2012-11-07 CN disclosed
US-20100216809-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-08-26 US disclosed
EP-2152271-A1 PIPERIDINE/PIPERAZINE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2010-02-17 EP disclosed
CN-101448802-A N-hydroxy-3-(4-{3-phenyl-S-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds as histone deacetylase inhibitors for the treatment of cancer DAC SRL (IT) 2009-06-03 CN disclosed
WO-2008148840-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-11 WO disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216809-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, DGAT2, DLAT MAPT 2039/4885ALDH1A1 488/4885KMT2A 825/4885
US-20170029440-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, PAOX, DGAT2 MAPT 2270/4885ALDH1A1 590/4885KMT2A 1091/4885
US-20140350012-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, PAOX, NNT MAPT 2026/4885ALDH1A1 629/4885KMT2A 1208/4885
US-20150322088-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, PAOX, DGAT2 MAPT 2270/4885ALDH1A1 590/4885KMT2A 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.